Higher-risk Myelodysplastic Syndrome: Clinical Trials

1 trial for Higher-risk Myelodysplastic Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow Higher-risk Myelodysplastic Syndrome: new trials by email Literature Review of Higher-risk Myelodysplastic Syndrome trials Research Report on Higher-risk Myelodysplastic Syndrome

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingCellCentric Ltd.2502019-08-092026-06-24

Narrower conditions

Hematologic Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Multiple Myeloma (1)

Broader conditions

Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)

Interventions

Azacitidine (1)  ·  Bortezomib (1)  ·  CCS1477 (1)  ·  Dexamethasone (1)  ·  Lenalidomide (1)  ·  daratumumab (1)  ·  ixazomib (1)  ·  pomalidomide (1)  ·  venetoclax (1)

Sponsors

CellCentric Ltd. (1)

Countries

France (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Tim Somervaille (1)